Navigation Links
Entry of Biogenerics and Decreasing Use of Amgen's Epogen and Johnson & Johnson's Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
Date:10/29/2007

Upheaval is Forecasted for the Markets of Five Chemotherapy Side Effect

Indications, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chemotherapy-induced anemia will decline by $2.8 billion over the next decade owing to the entry of several biogeneric products and decreasing use of erythropoiesis-stimulating proteins, including Amgen's Epogen and Johnson & Johnson's Procrit.

The new Pharmacor report entitled Managing the Side Effects of Chemotherapy finds that biogeneric erosion combined with emerging safety concerns and an increasingly restrictive reimbursement landscape for erythropoiesis-stimulating proteins will cause the chemotherapy-induced anemia market to decline from $4.5 billion in 2006 to $1.7 billion in 2016. The report also finds that the chemotherapy-induced neutropenia market will decrease $1 billion by 2016 because of the entry of biogeneric versions of Amgen's Neupogen in 2008 in Europe and in 2013 in the United States.

Sales for the most common side effects of chemotherapy-anemia, neutropenia, thrombocytopenia, chemotherapy-induced nausea and vomiting, and oral mucositis-totaled more than $8 billion in 2006 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. According to the report, the market is dominated by therapies that manage anemia and neutropenia effectively for most patients, but considerable opportunity remains for drugs that address thrombocytopenia and oral mucositis, indications characterized by a lack of effective therapies.

"There will be upheaval in the markets for all five of the indications we looked at," said Ramya Kollipara, Ph.D., analyst at Decision Resources. "The decline in drug-treatment rates and the introduction of biogenerics will substantially constrain the market f
'/>"/>

SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sentry Insurance to add 30 IT jobs in Fox Valley
2. Fiserv plans single entry point for loan processing online
3. Johnson Controls deals for asset-tracking software
4. Johnson Controls adds renewable energy unit
5. Johnson Controls unit lands contract for plug-in hybrid battery
6. Johnson Controls to expand in Europe
7. Johnson Controls partners on car satellite linkup
8. Florida schools employ Johnson Controls technology to stop sex predators
9. Johnson Controls partnership wins new contract
10. Johnson Controls appoints Roell to head EOC
11. Johnson Controls reports record quarterly sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... , EMERYVILLE, Calif., Aug. 6 Onyx Pharmaceuticals, ... to sell an aggregate of four million shares of its common stock ... million aggregate principal amount of its 4.00% convertible senior notes due 2016 ... options to purchase up to an additional 600,000 shares of its common ...
... , ALBANY, Ore., Aug. 6 Synthetech, Inc. (OTC ... of fiscal 2010, which ended June 30, 2009. Revenue for ... of $4.9 million in the first quarter of fiscal 2009. ... operating income of $314,000 for the same period last year. ...
... Md., Aug. 6 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ... of clinical-stage product candidates for central nervous system disorders, today announced ... on Monday, August 10, 2009, before the market opens. A full ... , , Mihael H. Polymeropoulos, M.D., President and ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 2
(Date:4/24/2014)... It,s broadly understood that the world,s oceans play ... exchange of carbon between Earth,s ecosystems and atmosphere. ... UC San Diego have taken a leap forward ... , When phytoplankton use carbon dioxide to make ... material is released into the sea as a ...
(Date:4/24/2014)... COLUMBIA, Mo. When bacteria attack plants, they ... cells to weaken and suppress natural defenses. However, ... the plant cells as a potential host. Now, ... and replicated the process that allows the bacteriaknown ... discovery could lead to natural anti-infective treatments that ...
(Date:4/24/2014)... April 24, 2014GEN Publishing recently introduced ... focusing on the application of OMICs technologies in ... sequencing, are beginning to transform medical care just ... the past decade-and-a-half. , "GEN,s editors and reporters ... genomics, metabolomics, transcriptomics, etc. etc. for years," said ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3Plants send out signals attracting harmful bacteria, MU study finds 2
... Mellon University,s Philip R. LeDuc and his collaborators in ... a protein that could ultimately unlock the mystery of ... role in the mechanics of biological processes in people. ... function of a protein that helps control cell behavior ...
... Reunion in the Indian Ocean and collaborating with researchers at ... sensitive night cameras to capture the first known occurrence of ... only is this the first time this behaviour has been ... who are better known for eating plants but ...
... number of scientists are merging methods and results from different ... team of researchers in a recent issue of Evolution ... new data, however, researchers who want to analyze previous findings ... the authors say. In a commentary piece in the journal ...
Cached Biology News:Carnegie Mellon's Philip LeDuc discovers new protein function 2First known instance of a cricket as an orchid pollinator captured on film by Kew scientist 2Biologists merge methods, results from different disciplines to find new meaning in old data 2Biologists merge methods, results from different disciplines to find new meaning in old data 3
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
... meet the needs of the ... medium supports fast cell growth ... while maintaining high cell viability ... using the Baculovirus Expression Vector ...
Mol wt: average mol wt12,360.96 Da by calculation...
Biology Products: